Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines

Shaji K. Kumar; Natalie S. Callander; Jens Hillengass; Michaela Liedtke; Muhamed Baljevic; Erica Campagnaro; Jorge J. Castillo; Jason C. Chandler; Robert F. Cornell; Caitlin Costello; Yvonne Efebera; Matthew Faiman; Alfred Garfall; Kelly Godby; Leona Holmberg; Myo Htut; Carol Ann Huff; Yubin Kang; Ola Landgren; Ehsan Malek; Thomas Martin; James Omel; Noopur Raje; Douglas Sborov; Seema Singhal; Keith Stockerl-Goldstein; Carlyn Tan; Donna Weber; Alyse Johnson-Chilla; Jennifer Keller; Rashmi Kumar

doi:10.6004/jnccn.2019.0049

Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines

Shaji K. Kumar, Natalie S. Callander, Jens Hillengass, Michaela Liedtke, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, Jason C. Chandler, Robert F. Cornell, Caitlin Costello, Yvonne Efebera, Matthew Faiman, Alfred Garfall, Kelly Godby, Leona Holmberg, Myo Htut, Carol Ann Huff, Yubin Kang, Ola Landgren, Ehsan MalekThomas Martin, James Omel, Noopur Raje, Douglas Sborov, Seema Singhal, Keith Stockerl-Goldstein, Carlyn Tan, Donna Weber, Alyse Johnson-Chilla, Jennifer Keller, Rashmi Kumar

Research output: Contribution to journal › Review article › peer-review

94 Scopus citations

Abstract

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.

Original language	English
Pages (from-to)	1154-1165
Number of pages	12
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	17
Issue number	10
DOIs	https://doi.org/10.6004/jnccn.2019.0049
State	Published - 2019

Access to Document

10.6004/jnccn.2019.0049

Cite this

Kumar, S. K., Callander, N. S., Hillengass, J., Liedtke, M., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Cornell, R. F., Costello, C., Efebera, Y., Faiman, M., Garfall, A., Godby, K., Holmberg, L., Htut, M., Huff, C. A., Kang, Y., Landgren, O., ... Kumar, R. (2019). Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 17(10), 1154-1165. https://doi.org/10.6004/jnccn.2019.0049

@article{9e327de769be438ca5506d49135c9b01,

title = "Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines",

abstract = "The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.",

author = "Kumar, {Shaji K.} and Callander, {Natalie S.} and Jens Hillengass and Michaela Liedtke and Muhamed Baljevic and Erica Campagnaro and Castillo, {Jorge J.} and Chandler, {Jason C.} and Cornell, {Robert F.} and Caitlin Costello and Yvonne Efebera and Matthew Faiman and Alfred Garfall and Kelly Godby and Leona Holmberg and Myo Htut and Huff, {Carol Ann} and Yubin Kang and Ola Landgren and Ehsan Malek and Thomas Martin and James Omel and Noopur Raje and Douglas Sborov and Seema Singhal and Keith Stockerl-Goldstein and Carlyn Tan and Donna Weber and Alyse Johnson-Chilla and Jennifer Keller and Rashmi Kumar",

note = "Funding Information: This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Genentech, Genomic Health, Inc., Novartis, Taiho Oncology, Inc., and TESARO. This activity is supported by an independent educational grant from AbbVie. This activity is supported by educational funding provided by Amgen. This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs. Funding Information: In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Publisher Copyright: {\textcopyright} 2019. All rights reserved.",

year = "2019",

doi = "10.6004/jnccn.2019.0049",

language = "English",

volume = "17",

pages = "1154--1165",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "10",

}

Kumar, SK, Callander, NS, Hillengass, J, Liedtke, M, Baljevic, M, Campagnaro, E, Castillo, JJ, Chandler, JC, Cornell, RF, Costello, C, Efebera, Y, Faiman, M, Garfall, A, Godby, K, Holmberg, L, Htut, M, Huff, CA, Kang, Y, Landgren, O, Malek, E, Martin, T, Omel, J, Raje, N, Sborov, D, Singhal, S, Stockerl-Goldstein, K, Tan, C, Weber, D, Johnson-Chilla, A, Keller, J & Kumar, R 2019, 'Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 17, no. 10, pp. 1154-1165. https://doi.org/10.6004/jnccn.2019.0049

TY - JOUR

T1 - Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines

AU - Kumar, Shaji K.

AU - Callander, Natalie S.

AU - Hillengass, Jens

AU - Liedtke, Michaela

AU - Baljevic, Muhamed

AU - Campagnaro, Erica

AU - Castillo, Jorge J.

AU - Chandler, Jason C.

AU - Cornell, Robert F.

AU - Costello, Caitlin

AU - Efebera, Yvonne

AU - Faiman, Matthew

AU - Garfall, Alfred

AU - Godby, Kelly

AU - Holmberg, Leona

AU - Htut, Myo

AU - Huff, Carol Ann

AU - Kang, Yubin

AU - Landgren, Ola

AU - Malek, Ehsan

AU - Martin, Thomas

AU - Omel, James

AU - Raje, Noopur

AU - Sborov, Douglas

AU - Singhal, Seema

AU - Stockerl-Goldstein, Keith

AU - Tan, Carlyn

AU - Weber, Donna

AU - Johnson-Chilla, Alyse

AU - Keller, Jennifer

AU - Kumar, Rashmi

N1 - Funding Information: This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Genentech, Genomic Health, Inc., Novartis, Taiho Oncology, Inc., and TESARO. This activity is supported by an independent educational grant from AbbVie. This activity is supported by educational funding provided by Amgen. This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs. Funding Information: In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Publisher Copyright: © 2019. All rights reserved.

PY - 2019

Y1 - 2019

N2 - The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.

AB - The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.

UR - http://www.scopus.com/inward/record.url?scp=85072968604&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2019.0049

DO - 10.6004/jnccn.2019.0049

M3 - Review article

C2 - 31590151

AN - SCOPUS:85072968604

SN - 1540-1405

VL - 17

SP - 1154

EP - 1165

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 10

ER -

Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this